Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here’s How Billionaire John Paulson Traded Valeant and His Other Top Stock Picks Last Quarter

Page 1 of 2

Hedge fund manager John Paulson, who founded Paulson & Co. back in 1994, has become very popular since he made a fortune betting against subprime mortgages in 2007. The billionaire investor started his hedge fund with only $2 million, and currently oversees more than $19 billion in assets. However, Paulson & Co. cannot be generally considered as a consistent hedge fund firm, thanks to the significant losses that it incurred in 2011 and 2012. Even so, Paulson’s decision to buy credit-default insurance against subprime mortgages points to the fact that he has a different and well-thought view on the markets and the U.S economy in general. The value of Paulson & Co.’s equity portfolio declined to $19.27 billion from $21.69 billion during the third quarter, owing to the turmoil in the stock markets and the fund’s rebalancing efforts. Having said that, let’s proceed with a discussion of John Paulson’s top stock picks at the end of the September quarter and their recent performance.


We track hedge funds and prominent investors because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 50 most popular large-cap stocks among hedge funds had a monthly alpha of about six means investors would have generated ten percentage points of alpha per year simply by imitating hedge funds’ top 15 small-cap ideas. We have been tracking the performance of these stocks since the end of August 2012 in real time and these stocks beat the market by 53 percentage points (102% return vs. the S&P 500’s 48.7% gain) over the last 38 months (see the details here).

John Paulson
John Paulson
Paulson & Co

#5 Starwood Hotels & Resorts Worldwide Inc. (NYSE:HOT)

 – Shares Owned by Paulson & Co. (as of September 30): 15.60 Million

 – Value of Holding (as of September 30): $1.04 Billion

Paulson & Co. lifted its stake in Starwood Hotels & Resorts Worldwide Inc. (NYSE:HOT) by 3.60 million shares during the third quarter. Earlier this week, Marriott International Inc. (NASDAQ:MAR) announced an agreement to buy the hotel and leisure company for approximately $12.2 billion, which would create the world’s largest lodging company. Under the terms of the merger agreement, Starwood’s shareholders are set to receive $2.00 in cash and 0.92 shares of Marriott common stock for each share of Starwood, which yields a compensation of roughly $68.95 per share at the time of writing. Marriott’s management anticipates that the merger could result in at least $200 million in annual cost savings in the second full-year after closing the merger. Daniel S. Och’s OZ Management added 4.97 million shares to its position in Starwood Hotels & Resorts Worldwide Inc. (NYSE:HOT) during the third quarter, which amounted to 11.24 million shares on September 30.

Follow Starwood Hotels & Resorts Worldwide Llc (NYSE:HOT)
Trade (NYSE:HOT) Now!


 – Shares Owned by Paulson & Co. (as of September 30): 6.81 Million

 – Value of Holding (as of September 30): $1.40 Billion

John Paulson’s hedge fund firm cut its exposure to Shire PLC (ADR) (NASDAQ:SHPG) by 289,900 shares during the September quarter, remaining with 6.81 million shares. Earlier this month, the biopharmaceutical company agreed to acquire Dyax Corp. (NASDAQ:DYAX) for $37.30 in cash per Dyax share, which yields an aggregate value of $5.9 billion. Just recently, Leerink Partners upgraded Shire to ‘Outperform’ from ‘Market Perform’ and raised its price target on the company’s stock to $239 from $220, citing recent promising OPUS-3 study results and the acquisition of Dyax. These recent developments could eventually bring in two high-potential drugs to Shire’s drug portfolio, which could boost the company’s top-line in the future. Samuel Isaly’s Orbimed Advisors reduced its position in Shire PLC (ADR) (NASDAQ:SHPG) by 641,600 shares during the latest quarter, owning 664,400 shares at the end of September.

Follow Shire Plc
Trade (SHPGY) Now!
Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!